If the clinical studies go according to plan, Fampridine could be submitted to the FDA for approval at the beginning of next year...so far it is helping those with MS walk better and slows down the degeneration process....BD
While there’s no cure for MS, the treatment options have grown in the last decade or so, with the approval of drugs including Avonex from Biogen Idec, Tysabri from Biogen and Elan, and Copaxone from Teva.
More MS drugs are on the horizon, with some taking new tacks on the disease. Ron Cohen, CEO of Acorda Therapeutics, talked with the Health Blog about the landscape for MS treatment and the prospects for Fampridine-SR, a medicine his company licensed from Elan.
Health Blog : Experimental Drug May Help Multiple Sclerosis Patients Walk
0 comments :
Post a Comment